Anti-PD-L1-mlgG1e3 InvivoFit™ is a recombinant monoclonal antibody (mAb) designed for in vivo studies in mice. This mAb features the variable region of the previously described anti-PD-L1 atezolizumab and the engineered murine IgG1e3 constant region. Atezolizumab (formerly known as MPDL3280A) is a therapeutic mAb that targets programmed cell death ligand 1 (PD-L1), blocking its interaction with the receptor, PD-1. This mAb binds both murine and human PD-L1.

The binding capacity of Anti-PD-L1-mlgG1e3 InvivoFit™ was compared to a commercially available anti-PD-L1 mAb using ELISA (data below). Anti-PD-L1-mlgG1e3 InvivoFit™ recognizes both murine and human PD-L1, unlike the commercially available anti-PD-L1 clone 10F-9G2.

**A: Evaluation of mPD-L1 binding**

ELISA binding of Anti-PD-L1-mlgG1e3 InvivoFit™ to recombinant PD-L1. A dilution series of Anti-PD-L1-mlgG1e3 InvivoFit™ and anti-PD-L1 clone 10F-9G2 was used for the detection of coated murine PD-L1 (A) or human PD-L1 (B) antigen at 2 µg/ml. Bound antibody was detected using either an HRP-conjugated anti-murine IgG secondary antibody for Anti-PD-L1-mlgG1e3 InvivoFit™ or an HRP-conjugated anti-rat IgG2b secondary antibody for anti-PD-L1 clone 10F-9G2. HRP activity was assessed by a colorimetric assay using Tetramethylbenzidine (TMB) substrate. Optical density was measured at 490 nm. Data are shown as percentage absorbance.